HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $35 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Tempest Therapeutics (NASDAQ:TPST) and maintains a $35 price target.
June 05, 2023 | 10:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Tempest Therapeutics and maintains a $35 price target.
The reiteration of the Buy rating and maintenance of the $35 price target by HC Wainwright & Co. analyst Joseph Pantginis indicates a positive outlook for Tempest Therapeutics. This news is likely to have a positive short-term impact on TPST's stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100